{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:16:45Z","timestamp":1788225405658,"version":"build-2803163510"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04045-2","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T13:05:18Z","timestamp":1758114318000},"page":"4142-4159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["SEOM\u2013SOGUG clinical guideline for urothelial cancer (2025)"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-1331","authenticated-orcid":false,"given":"Javier","family":"Puente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejo","family":"Rodr\u00edguez-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sevillano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio V\u00e1zquez","family":"Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos \u00c1lvarez","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Chirivella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidio","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso G\u00f3mez","family":"de Lia\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a P.","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"4045_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234\u201341. https:\/\/doi.org\/10.1016\/j.eururo.2012.07.033.","journal-title":"Eur Urol"},{"key":"4045_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s12094-022-02815-w","volume":"24","author":"BP Valderrama","year":"2022","unstructured":"Valderrama BP, Gonz\u00e1lez-Del-Alba A, Morales-Barrera R, Pel\u00e1ez Fern\u00e1ndez I, V\u00e1zquez S, Caballero D\u00edaz C, et al. SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021). Clin Transl Oncol. 2022;24:613\u201324. https:\/\/doi.org\/10.1007\/s12094-022-02815-w.","journal-title":"Clin Transl Oncol"},{"key":"4045_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"4045_CR4","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM). Las cifras del c\u00e1ncer en Espa\u00f1a 2025. https:\/\/seom.org\/publicaciones\/el-cancer-en-espa\u00f1a.com. Accessed 17 Jun 2025."},{"key":"4045_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","volume":"84","author":"I Jubber","year":"2023","unstructured":"Jubber I, Ong S, Bukavina L, Black PC, Comp\u00e9rat E, Kamat AM, et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur Urol. 2023;84:176\u201390. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.029.","journal-title":"Eur Urol"},{"key":"4045_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000335","volume":"3","author":"EBA Chandran","year":"2024","unstructured":"Chandran EBA, Iannantuono GM, Atiq SO, Akbulut D, Sinaii N, Simon NI, et al. Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis. BMJ Oncol. 2024;3:e000335. https:\/\/doi.org\/10.1136\/bmjonc-2024-000335.","journal-title":"BMJ Oncol"},{"key":"4045_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","volume":"82","author":"GJ Netto","year":"2022","unstructured":"Netto GJ, Amin MB, Berney DM, Comp\u00e9rat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors. Eur Urol. 2022;82:469\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2022.07.002.","journal-title":"Eur Urol"},{"key":"4045_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2024;85:17\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.016.","journal-title":"Eur Urol"},{"key":"4045_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y, Sj\u00f6dahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420\u201333. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.006.","journal-title":"Eur Urol"},{"key":"4045_CR10","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtr\u00f6der K, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12:2301. https:\/\/doi.org\/10.1038\/s41467-021-22465-w.","journal-title":"Nat Commun"},{"key":"4045_CR11","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2217\/fon-2016-0042","volume":"12","author":"E di Martino","year":"2016","unstructured":"di Martino E, Tomlinson DC, Williams SV, Knowles MA. A place for precision medicine in bladder cancer: targeting the FGFRs. Future Oncol. 2016;12:2243\u201363. https:\/\/doi.org\/10.2217\/fon-2016-0042.","journal-title":"Future Oncol"},{"key":"4045_CR12","volume-title":"AJCC cancer staging manual","author":"MB Amin","year":"2017","unstructured":"Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.","edition":"8"},{"key":"4045_CR13","doi-asserted-by":"crossref","unstructured":"Gontero P, Birtle A, Comp\u00e9rat E, Dominguez Escrig JL, Liedberg F, Mariappan P, et al. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). 2025. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2025.pdf. Accessed 23 Jun 2025.","DOI":"10.1016\/j.eururo.2026.04.009"},{"key":"4045_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"RJ Sylvester","year":"2016","unstructured":"Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol. 2016;69:231\u201344. https:\/\/doi.org\/10.1016\/j.eururo.2015.05.050.","journal-title":"Eur Urol"},{"key":"4045_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56:247\u201356. https:\/\/doi.org\/10.1016\/j.eururo.2009.04.038.","journal-title":"Eur Urol"},{"key":"4045_CR16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63:462\u201372. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.039.","journal-title":"Eur Urol"},{"key":"4045_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumigui\u00e9 M, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22:919\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(21)00147-9.","journal-title":"Lancet Oncol"},{"key":"4045_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bju.12121","volume":"113","author":"RK Lee","year":"2014","unstructured":"Lee RK, Abol-Enein H, Artibani W, Bochner B, Dalbagni G, Daneshmand S, et al. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int. 2014;113:11\u201323. https:\/\/doi.org\/10.1111\/bju.12121.","journal-title":"BJU Int"},{"key":"4045_CR19","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa2401497","volume":"391","author":"SP Lerner","year":"2024","unstructured":"Lerner SP, Tangen C, Svatek RS, Daneshmand S, Pohar KS, Skinner E, et al. Standard or extended lymphadenectomy for muscle-invasive bladder cancer. N Engl J Med. 2024;391:1206\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2401497.","journal-title":"N Engl J Med"},{"key":"4045_CR20","unstructured":"Bladder cancer: diagnosis and clinical management 1st ed. Lerner SP, Schoenberg MP, Sternberg CN, editors. Hoboken: Wiley-Blackwell; 2015."},{"key":"4045_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","volume":"22","author":"A Choudhury","year":"2021","unstructured":"Choudhury A, Porta N, Hall E, Song YP, Owen R, MacKay R, et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 2021;22:246\u201355. https:\/\/doi.org\/10.1016\/S1470-2045(20)30607-0.","journal-title":"Lancet Oncol"},{"key":"4045_CR22","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","volume":"14","author":"CM Coppin","year":"1996","unstructured":"Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996;14:2901\u20137. https:\/\/doi.org\/10.1200\/JCO.1996.14.11.2901.","journal-title":"J Clin Oncol"},{"key":"4045_CR23","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477\u201388. https:\/\/doi.org\/10.1056\/NEJMoa1106106.","journal-title":"N Engl J Med"},{"key":"4045_CR24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"T Mitin","year":"2013","unstructured":"Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013;14:863\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(13)70255-9.","journal-title":"Lancet Oncol"},{"key":"4045_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.18.00537","volume":"37","author":"JJ Coen","year":"2019","unstructured":"Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, et al. Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712-a randomized phase II trial. J Clin Oncol. 2019;37:44\u201351. https:\/\/doi.org\/10.1200\/JCO.18.00537.","journal-title":"J Clin Oncol"},{"key":"4045_CR26","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G, et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023;24:669\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(23)00170-5.","journal-title":"Lancet Oncol"},{"key":"4045_CR27","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bju.16366","volume":"134","author":"F Ditonno","year":"2024","unstructured":"Ditonno F, Veccia A, Montanaro F, Pettenuzzo G, Franco A, Manfredi C, et al. Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies. BJU Int. 2024;134:684\u201395. https:\/\/doi.org\/10.1111\/bju.16366.","journal-title":"BJU Int"},{"key":"4045_CR28","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.ijrobp.2016.11.056","volume":"97","author":"V Vashistha","year":"2017","unstructured":"Vashistha V, Wang H, Mazzone A, Liss MA, Svatek RS, Schleicher M, et al. Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2017;97:1002\u201320. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.11.056.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4045_CR29","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"G Griffiths","year":"2011","unstructured":"Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK, International Collaboration of Trialists, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171\u20137. https:\/\/doi.org\/10.1200\/JCO.2010.32.3139.","journal-title":"J Clin Oncol"},{"key":"4045_CR30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859\u201366. https:\/\/doi.org\/10.1056\/NEJMoa022148.","journal-title":"N Engl J Med"},{"key":"4045_CR31","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/s0140-6736(03)13580-5","volume":"361","author":"Advanced Bladder Cancer Meta-analysis Collaboration","year":"2003","unstructured":"Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361:1927\u201334. https:\/\/doi.org\/10.1016\/s0140-6736(03)13580-5.","journal-title":"Lancet"},{"key":"4045_CR32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/01.ju.0000090967.08622.33","volume":"171","author":"E Winquist","year":"2004","unstructured":"Winquist E, Kirchner TS, Segal R, Chin J, Lukka H, Genitourinary Cancer Disease Site Group, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004;171:561\u20139. https:\/\/doi.org\/10.1097\/01.ju.0000090967.08622.33.","journal-title":"J Urol"},{"key":"4045_CR33","doi-asserted-by":"publisher","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202\u20135. https:\/\/doi.org\/10.1016\/j.eururo.2005.04.006.","DOI":"10.1016\/j.eururo.2005.04.006"},{"key":"4045_CR34","doi-asserted-by":"publisher","first-page":"S678","DOI":"10.1016\/j.annonc.2021.08.048","volume":"32","author":"C Pfister","year":"2021","unstructured":"Pfister C, Gravis G, Flechon A, Chevreau CM, Mahammedi H, Laguerre B, et al. 652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): results of the GETUG\/AFU VESPER V05 phase III trial [ESMO abstract]. Ann Oncol. 2021;32:S678. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.048.","journal-title":"Ann Oncol"},{"key":"4045_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","volume":"25","author":"C Pfister","year":"2024","unstructured":"Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, et al. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol. 2024;25:255\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(23)00587-9.","journal-title":"Lancet Oncol"},{"key":"4045_CR36","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1001\/jamaoncol.2018.3542","volume":"4","author":"CC Peyton","year":"2018","unstructured":"Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. JAMA Oncol. 2018;4:1535\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3542.","journal-title":"JAMA Oncol"},{"key":"4045_CR37","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1200\/JCO.2014.55.4055","volume":"32","author":"CN Sternberg","year":"2014","unstructured":"Sternberg CN, Apolo AB. Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer. J Clin Oncol. 2014;32:1868\u201370. https:\/\/doi.org\/10.1200\/JCO.2014.55.4055.","journal-title":"J Clin Oncol"},{"key":"4045_CR38","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med. 2024;391:1773\u201386. https:\/\/doi.org\/10.1056\/NEJMoa2408154.","journal-title":"N Engl J Med"},{"key":"4045_CR39","doi-asserted-by":"publisher","unstructured":"Paz-Ares LG, Solsona E, Esteban E, Saez A, Gonzalez-Larriba J, Anton A, et al. Randomized phase III trial comparing adjuvant paclitaxel\/gemcitabine\/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99\/01 study [ASCO abstract]. J Clin Oncol. 2010;28:LBA4518. https:\/\/doi.org\/10.1200\/jco.2010.28.18_suppl.lba4518.","DOI":"10.1200\/jco.2010.28.18_suppl.lba4518"},{"key":"4045_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","volume":"81","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group","year":"2022","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group. Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials. Eur Urol. 2022;81:50\u201361. https:\/\/doi.org\/10.1016\/j.eururo.2021.09.028.","journal-title":"Eur Urol"},{"key":"4045_CR41","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384:2102\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2034442.","journal-title":"N Engl J Med"},{"key":"4045_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.24.00340","volume":"43","author":"MD Galsky","year":"2025","unstructured":"Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274. J Clin Oncol. 2025;43:15\u201321. https:\/\/doi.org\/10.1200\/JCO.24.00340.","journal-title":"J Clin Oncol"},{"key":"4045_CR43","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.2025.43.5_suppl.658","volume":"43","author":"MI Milowsky","year":"2025","unstructured":"Milowsky MI, Galsky MD, Witjes JA, Gschwend JE, Schenker M, Perez Valderrama B, et al. Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274 [ASCO abstract]. J Clin Oncol. 2025;43:658. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.658.","journal-title":"J Clin Oncol"},{"key":"4045_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl J Med. 2025;392:45\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2401726.","journal-title":"N Engl J Med"},{"key":"4045_CR45","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:525\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(21)00004-8.","journal-title":"Lancet Oncol"},{"key":"4045_CR46","unstructured":"van der Heijden AG, Bruins HM, Carrion A, Cathomas R, Comp\u00e9rat EM, Dimitropoulos K, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer. 2023. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Muscle-Invasive-Bladder-Cancer-2025.pdf. Accessed 23 Jun 2025."},{"key":"4045_CR47","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","volume":"10","author":"PJ Loehrer Sr.","year":"1992","unstructured":"Loehrer PJ Sr., Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066\u201373. https:\/\/doi.org\/10.1200\/JCO.1992.10.7.1066.","journal-title":"J Clin Oncol"},{"key":"4045_CR48","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602\u20138. https:\/\/doi.org\/10.1200\/JCO.2005.07.757.","journal-title":"J Clin Oncol"},{"key":"4045_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","volume":"42","author":"CN Sternberg","year":"2006","unstructured":"Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42:50\u20134. https:\/\/doi.org\/10.1016\/j.ejca.2005.08.032.","journal-title":"Eur J Cancer"},{"key":"4045_CR50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","volume":"12","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12:211\u20134. https:\/\/doi.org\/10.1016\/S1470-2045(10)70275-8.","journal-title":"Lancet Oncol"},{"key":"4045_CR51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2012","unstructured":"De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30:191\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.37.3571.","journal-title":"J Clin Oncol"},{"key":"4045_CR52","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2002788.","journal-title":"N Engl J Med"},{"key":"4045_CR53","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.22.01792","volume":"41","author":"T Powles","year":"2023","unstructured":"Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Ull\u00e9n A, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up. J Clin Oncol. 2023;41:3486\u201392. https:\/\/doi.org\/10.1200\/JCO.22.01792.","journal-title":"J Clin Oncol"},{"key":"4045_CR54","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Arija J\u00c1A, Bamias A, Davis ID, De Santis M, Kikuchi E, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1547\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(20)30230-0.","journal-title":"Lancet"},{"key":"4045_CR55","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M, Matsubara N, G\u00e9czi L, Cheng SY, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:931\u201345. https:\/\/doi.org\/10.1016\/S1470-2045(21)00152-2.","journal-title":"Lancet Oncol"},{"key":"4045_CR56","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1574\u201388. https:\/\/doi.org\/10.1016\/S1470-2045(20)30541-6.","journal-title":"Lancet Oncol"},{"key":"4045_CR57","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389:1778\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2309863.","journal-title":"N Engl J Med"},{"key":"4045_CR58","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2312117.","journal-title":"N Engl J Med"},{"issue":"5_suppl","key":"4045_CR59","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1200\/JCO.2025.43.5_suppl.664","volume":"43","author":"T Powles","year":"2025","unstructured":"Powles T, Van Der Heijden MS, Loriot Y, Bedke J, Valderrama BP, Iyer G, et al. EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la\/mUC). J Clin Oncol. 2025;43(5_suppl):664. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.664.","journal-title":"J Clin Oncol"},{"key":"4045_CR60","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(16)32455-2.","journal-title":"Lancet"},{"key":"4045_CR61","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O\u2019Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(17)30616-2.","journal-title":"Lancet Oncol"},{"key":"4045_CR62","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","volume":"34","author":"AV Balar","year":"2023","unstructured":"Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, et al. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol. 2023;34:289\u201399. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.012.","journal-title":"Ann Oncol"},{"key":"4045_CR63","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(17)33297-X.","journal-title":"Lancet"},{"key":"4045_CR64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eururo.2021.03.024","volume":"80","author":"MS van der Heijden","year":"2021","unstructured":"van der Heijden MS, Loriot Y, Dur\u00e1n I, Ravaud A, Retz M, Vogelzang NJ, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma: a long-term overall survival and safety update from the phase 3 IMvigor211 clinical trial. Eur Urol. 2021;80:7\u201311. https:\/\/doi.org\/10.1016\/j.eururo.2021.03.024.","journal-title":"Eur Urol"},{"key":"4045_CR65","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2035807.","journal-title":"N Engl J Med"},{"key":"4045_CR66","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","volume":"34","author":"JE Rosenberg","year":"2023","unstructured":"Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL, et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. 2023;34:1047\u201354. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.016.","journal-title":"Ann Oncol"},{"key":"4045_CR67","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389:1961\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2308849.","journal-title":"N Engl J Med"},{"key":"4045_CR68","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonz\u00e1lez-Mart\u00edn A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42:47\u201358. https:\/\/doi.org\/10.1200\/JCO.23.02005.","journal-title":"J Clin Oncol"},{"key":"4045_CR69","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","volume":"35","author":"F Soria","year":"2017","unstructured":"Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017;35:379\u201387. https:\/\/doi.org\/10.1007\/s00345-016-1928-x.","journal-title":"World J Urol"},{"key":"4045_CR70","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.juro.2012.04.009","volume":"188","author":"M Rink","year":"2012","unstructured":"Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, et al. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol. 2012;188:398\u2013404. https:\/\/doi.org\/10.1016\/j.juro.2012.04.009.","journal-title":"J Urol"},{"key":"4045_CR71","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1002\/cncr.24339","volume":"115","author":"BA Inman","year":"2009","unstructured":"Inman BA, Tran VT, Fradet Y, Lacombe L. Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. Cancer. 2009;115:2853\u201362. https:\/\/doi.org\/10.1002\/cncr.24339.","journal-title":"Cancer"},{"key":"4045_CR72","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","volume":"73","author":"M Roupr\u00eat","year":"2018","unstructured":"Roupr\u00eat M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73:111\u201322. https:\/\/doi.org\/10.1016\/j.eururo.2017.07.036.","journal-title":"Eur Urol"},{"key":"4045_CR73","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.eururo.2008.08.008","volume":"54","author":"M Roupr\u00eat","year":"2008","unstructured":"Roupr\u00eat M, Yates DR, Comperat E, Cussenot O. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol. 2008;54:1226\u201336. https:\/\/doi.org\/10.1016\/j.eururo.2008.08.008.","journal-title":"Eur Urol"},{"key":"4045_CR74","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2012.02.030","volume":"62","author":"G Lughezzani","year":"2012","unstructured":"Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012;62:100\u201314. https:\/\/doi.org\/10.1016\/j.eururo.2012.02.030.","journal-title":"Eur Urol"},{"key":"4045_CR75","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cncr.24135","volume":"115","author":"V Margulis","year":"2009","unstructured":"Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115:1224\u201333. https:\/\/doi.org\/10.1002\/cncr.24135.","journal-title":"Cancer"},{"key":"4045_CR76","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395:1268\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(20)30415-3.","journal-title":"Lancet"},{"key":"4045_CR77","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/JCO.23.01659","volume":"42","author":"AJ Birtle","year":"2024","unstructured":"Birtle AJ, Jones R, Chester J, Lewis R, Biscombe K, Johnson M, et al. Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: final results of the POUT trial. J Clin Oncol. 2024;42:1466\u201371. https:\/\/doi.org\/10.1200\/JCO.23.01659.","journal-title":"J Clin Oncol"},{"key":"4045_CR78","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.euo.2020.12.007","volume":"4","author":"JP Sfakianos","year":"2021","unstructured":"Sfakianos JP, Gul Z, Shariat SF, Matin SF, Daneshmand S, Plimack E, et al. Genetic differences between bladder and upper urinary tract carcinoma: implications for therapy. Eur Urol Oncol. 2021;4:170\u20139. https:\/\/doi.org\/10.1016\/j.euo.2020.12.007.","journal-title":"Eur Urol Oncol"},{"key":"4045_CR79","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/CU9.0000000000000189","volume":"17","author":"S Taktak","year":"2023","unstructured":"Taktak S, El-Taji O, Hanchanale V. Modern methods in managing urachal adenocarcinoma. Curr Urol. 2023;17:188\u201392. https:\/\/doi.org\/10.1097\/CU9.0000000000000189.","journal-title":"Curr Urol"},{"key":"4045_CR80","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.urology.2006.10.029","volume":"69","author":"MD Galsky","year":"2007","unstructured":"Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007;69:255\u20139. https:\/\/doi.org\/10.1016\/j.urology.2006.10.029.","journal-title":"Urology"},{"key":"4045_CR81","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00200","volume":"8","author":"A Cigliola","year":"2024","unstructured":"Cigliola A, Basnet A, Jacob JM, Mercinelli C, Tateo V, Patan\u00e8 DA, et al. Urachal and nonurachal adenocarcinomas of the urinary bladder: a comprehensive genomic profiling study. JCO Precis Oncol. 2024;8:e2400200. https:\/\/doi.org\/10.1200\/PO.24.00200.","journal-title":"JCO Precis Oncol"},{"key":"4045_CR82","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nrurol.2011.48","volume":"8","author":"M Teo","year":"2011","unstructured":"Teo M, Swan NC, McDermott RS. Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab. Nat Rev Urol. 2011;8:282\u20135. https:\/\/doi.org\/10.1038\/nrurol.2011.48.","journal-title":"Nat Rev Urol"},{"key":"4045_CR83","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clgc.2022.05.005","volume":"20","author":"MY Teo","year":"2022","unstructured":"Teo MY, Guercio BJ, Arora A, Hao X, Regazzi AM, Donahue T, et al. Long-term outcomes of local and metastatic small cell carcinoma of the urinary bladder and genomic analysis of patients treated with neoadjuvant chemotherapy. Clin Genitourin Cancer. 2022;20:431\u201341. https:\/\/doi.org\/10.1016\/j.clgc.2022.05.005.","journal-title":"Clin Genitourin Cancer"},{"key":"4045_CR84","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JU.0000000000000761","volume":"204","author":"NJ Miller","year":"2020","unstructured":"Miller NJ, Khaki AR, Diamantopoulos LN, Bilen MA, Santos V, Agarwal N, et al. Histological subtypes and response to PD-1\/PD-L1 blockade in advanced urothelial cancer: a retrospective study. J Urol. 2020;204:63\u201370. https:\/\/doi.org\/10.1097\/JU.0000000000000761.","journal-title":"J Urol"},{"key":"4045_CR85","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1200\/JCO.2022.40.6_suppl.529","volume":"40","author":"K Case","year":"2022","unstructured":"Case K, Martini DJ, Dababneh M, Nazha B, Brown JT, Joshi SS, et al. Expression of Nectin-4 and PD-L1 in bladder cancer with variant histology [ASCO genitourinary cancers symposium abstract]. J Clin Oncol. 2022;40:529. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.529.","journal-title":"J Clin Oncol"},{"key":"4045_CR86","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1200\/JCO.2024.42.4_suppl.652","volume":"42","author":"T Jindal","year":"2024","unstructured":"Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Nizam A, Basu A, et al. Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: analysis of the UNITE study [ASCO genitourinary cancers symposium abstract]. J Clin Oncol. 2024;42:652. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.652.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04045-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04045-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04045-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:03:42Z","timestamp":1788224622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04045-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":86,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4045"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04045-2","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: to remove personal email address Alfonso G\u00f3mez de Lia\u00f1o.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Javier Puente\n                      has received speaker fees and attended advisory boards for Astellas, MSD, Janssen, Roche, Eisai, Bayer, AstraZeneca, and Ipsen; has received grants and attended an advisory board for Merck; has received speaker fees from BMS; and has received speaker fees and grants, and attended advisory boards for Gilead and Novartis.\n                      Alejo Rodr\u00edguez-Vida\n                      has received speaker fees and attended advisory boards for Astellas, MSD, BMS, and Merck.\n                      Sergio V\u00e1zquez Est\u00e9vez\n                      has received speaker fees and attended advisory boards for Astellas, BMS, Merck, MSD, and Roche.\n                      Carlos \u00c1lvarez Fern\u00e1ndez\n                      has received speaker fees and attended advisory boards for Pfizer and Bayer; and has received speaker fees from AstraZeneca, Merck\/Pfizer, BMS, and MSD.\n                      Miguel \u00c1ngel Climent\n                      has received speaker fees from AstraZeneca and BMS; has attended advisory boards for Astellas and MSD; has received speaker fees and attended an advisory board for Merck; and has received a grant from Janssen.\n                      Ovidio Fern\u00e1ndez\n                      has attended an advisory board for Pfizer; has received speaker fees from Astellas, Bayer, BMS, AstraZeneca, MSD, and Regeneron; and has received speaker fees and attended advisory boards for Janssen, AAA-Novartis, and Pierre Fabre.\n                      Alfonso G\u00f3mez de Lia\u00f1o\n                      has received non-financial support and other fees and attended advisory boards for AstraZeneca and MSD; has received speaker fees and attended an advisory board for Astellas; has received speaker fees and a grant from BMS; has received other fees from Gilead; has received speaker and other fees and attended an advisory board for Johnson & Johnson; has received non-financial support from Merck; and has received non-financial support and attended an advisory board for Roche.\n                      Bego\u00f1a P\u00e9rez Valderrama\n                      has received speaker and other fees and attended advisory boards for Bristol-Myers Squibb, Pfizer, Astellas, Merck, MSD, and AstraZeneca; has received speaker fees and attended advisory boards for Bayer and AAA HealthCare; has attended advisory boards for Janssen Oncology and Recordati; has received speaker fees from Almirall Pharma; and has received other fees from Roche.\n                      Elena Sevillano\n                      and\n                      Isabel Chirivella\n                      declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","label":"Ethics approval and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}